Conference Call with Torrent Pharmaceuticals Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Torrent Pharmaceuticals announced Q2FY25 results Revenue at Rs 2,889 crore grew by 9%, compared to Rs 2,660 during Q2FY24. Gross pprofit: Rs 2,211 crore change 11%, Operating EBITDA margin at 32.5%. Operating EBITDA at Rs 939 crore, compared to Rs 825 crore during Q2FY24, change 14%. Net Profit after tax at Rs 453 crore, compared to Rs 386 crore during Q2FY24, change 17%. Insulin revenues were impacted this quarter due to scheduled shutdown taken in the month of August for maintenance activities. The facility will be released for manufacturing in December. Shortfall is significantly planned to be recovered in Quarter 4 of this year and consequently there will not be any impact on a full year basis. Adjusted for the above, the underlying revenue growth for the quarter is 10% with Operating EBITDA growth at 16%. Result PDF